ICON PLC (ICLR) News
Filter ICLR News Items
ICLR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ICLR News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest ICLR News From Around the Web
Below are the latest news stories about ICON PLC that investors may wish to consider to help them evaluate ICLR as an investment opportunity.
What Makes ICON Public Limited Company (ICLR) a Prospective Investment?ClearBridge Investments, an investment management company, released its “ClearBridge Large Cap Growth Strategy” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. During a time of momentum-driven returns and heightened investor optimism following Donald Trump’s re-election, the more defensively oriented Strategy lagged behind. The S&P 500 Index advanced 2.41% in […] |
Biomarker and Trial Optimisation Needed to Drive R&D Progress in Alzheimer’s and Related Disorders – ICON SurveyDUBLIN, January 08, 2025--ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today released the findings of a survey of over 120 biotech and pharma professionals developing treatments for neurodegenerative disorders. The findings indicate that, despite recent successes in developing disease modifying treatments for Alzheimer's, persistent challenges that remain in neurodegenerative clinical trials can be mitigated by underutilised trial me |
Icon price target lowered to $290 from $300 at CitiCiti lowered the firm’s price target on Icon (ICLR) to $290 from $300 and keeps a Buy rating on the shares. Outside of the preannouncements and guidance updates from life science tools and diagnostics names in January, Citi expects key themes to include the cadence and magnitude of the expected recoveries in areas such as China and bioprocessing, the rollout of the China stimulus program, trends within the instrumentation replacement cycle, general biopharma health and its possible impact on cli |
ICON plc to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceDUBLIN, January 07, 2025--ICON plc to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
ICON Public Limited Company (ICLR) Slid on Drop in Biotechnology FundingAmerican Century Investments, an investment management company, released its “International Growth Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here. Despite periods of volatility, equity markets held steady and ended the quarter higher as interest rates were lowered by central banks. Small-cap stocks outperformed large caps, and value narrowly […] |
ICON and Its Employees Celebrated for Excellence in the Field of Clinical ResearchDUBLIN, December 23, 2024--ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been honoured with numerous awards in the second half of 2024. |
ICON Announces Appointment of Chief Operating OfficerDUBLIN, December 18, 2024--ICON Announces Appointment of Chief Operating Officer |
Are ICON Public Limited Company's (NASDAQ:ICLR) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?ICON (NASDAQ:ICLR) has had a rough three months with its share price down 29%. However, the company's fundamentals look... |
ICON Public Limited Company (ICLR) Fell on Reduced GuidanceTimesSquare Capital Management, an equity investment management company, released its “U.S. Mid Cap Growth Strategy” third-quarter investor letter. A copy of the letter can be downloaded here. Within equities, smaller or value-oriented stocks in developed economies yielded higher, whereas emerging markets saw the opposite trend. In the third quarter, the strategy returned 4.96% (gross) and […] |
ICON Public Limited Company (ICLR) Fell Along with PeersPolen Capital, an investment management company, released its “Polen International Growth Strategy” third-quarter 2024 investor letter. A copy of the letter can be downloaded here. The strategy rose 3.25% (net of fees) in the third quarter compared to an 8.06% return for the MSCI ACWI (ex-USA) index. After a relatively peaceful first half of 2024, […] |